European drugmakers say they are ‘losing ground’ to US and Chinese rivals
European pharmaceutical leaders report a decline in global competitiveness, specifically in acquisitions and research. While executives from firms like Roche, Novartis, and AstraZeneca seek increased spending and faster clinical trials, Chinese firms are disrupting the supply chain. Two Chinese companies now produce drug-filling machines at half the cost of European giants, supporting low-cost drug production in India. This coincides with a $440 billion patent cliff that is pushing Western biopharma companies toward Chinese biotech partnerships.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Executives from AstraZeneca, Novartis, and Roche are calling for higher spending and faster clinical trials.
- ✓ Western biopharma companies are partnering with Chinese biotech firms as $440 billion in drugs approach a patent cliff.
What changed
Chinese manufacturers are now undercutting European drug-filling machine prices by half.
Live updates
-
European pharma loses ground to US and Chinese competitors
European pharmaceutical leaders report a decline in global competitiveness, specifically in acquisitions and research. While executives from firms like Roche, Novartis, and AstraZeneca seek increased spending and faster clinical trials, Chinese firms are disrupting the supply chain. Two Chinese companies now produce drug-filling machines at half the cost of European giants, supporting low-cost drug production in India. This coincides with a $440 billion patent cliff that is pushing Western biopharma companies toward Chinese biotech partnerships.
Why it matters
The pharmaceutical sector faces a massive shift as older patents expire, creating a vacuum for next-generation medicines. Europe struggles with regulatory delays and internal divisions over deal dominance. This allows US and Chinese rivals to capture more market share in both innovation and manufacturing.
What is confirmed
- Executives from AstraZeneca, Novartis, and Roche are calling for higher spending and faster clinical trials.
- Western biopharma companies are partnering with Chinese biotech firms as $440 billion in drugs approach a patent cliff.
Still unconfirmed
- European biotech leaders agree that Europe is losing ground in acquisitions.
What to watch next
- European regulatory changes to accelerate clinical trial timelines
- Investment figures for next-generation medicines in the EU
- Further shifts in biopharma partnership agreements toward China
confidence 80%Sources used for this update (3)
- catalystalert.io — European biotech leaders split on US-China fight for deal ...
- decodingthedragon.substack.com — #112: Why does China build drug-filling machines at half ...
- www.businesspost.ie — Pharmaceuticals - Business Post
-
European Drugmakers Warn Region Is Falling Behind US and China
Chairs of nine major European pharmaceutical companies warn that Europe is losing ground in the global drug sector, pointing to declining research shares and clinical trials. Executives from firms including AstraZeneca, Novartis, and Roche demand higher spending and faster clinical trials to attract investments in next-generation medicines. Meanwhile, Western biopharma companies turn to Chinese biotech partners as the industry approaches a massive patent cliff involving $440 billion in drugs, while European leaders remain split on deal dominance and face regulatory delays.
Why it matters
Europe has slid from a dominant global leader to a trailing player over the past two decades, with its share of global pharmaceutical research and development dropping from 43 percent in 1990 to 31 percent by 2025. Italian economist Mario Draghi projects that this downward trajectory will continue. The European Federation of Pharmaceutical Industries and Associations notes that while EU research spending grew at an annual rate of 5.14 percent between 2010 and 2024, US spending grew at 6 percent annually on a much larger base. And commercial clinical trials in Europe halved over the past decade.
What is confirmed
- Chairs of nine major European pharmaceutical companies, including AstraZeneca, Novartis, and Roche, warned that the region is losing ground to rivals in the United States and China.
- Goldman Sachs analyst Salveen Richter stated that big pharma is shopping in China biotech as $440 billion in drugs lose patents.
- European pharmaceutical research and development share dropped from 43 percent in 1990 to 31 percent.
- Commercial clinical trials run in Europe almost halved over the last 10 years and now trail China.
Still unconfirmed
- A major Dutch haul occurs despite European drugmakers and investors warning the region is losing ground in the global pharmaceutical market.
What to watch next
- Progress on the EU Biotechnology Act proposed last year.
- Decisions by European policymakers on increasing spending and accelerating clinical trials.
confidence 95%Sources used for this update (14)
- en.wikipedia.org — Europe - Wikipedia
- ontheworldmap.com — Map of Europe | List of Countries of Europe Alphabetically
- european-union.europa.eu — Your gateway to the EU, News, Highlights | European Union
- en.wikipedia.org — European Union - Wikipedia
- commission.europa.eu — European Commission, official website - European Commission
- european-union.europa.eu — EU countries - European Union
- worldpopulationreview.com — List of Countries in the European Union 2026
- www.pharmexec.com — Global | Topic | PharmExec
- finance.yahoo.com — Goldman Sachs Says China Biotech Is Where Big Pharma Is ...
- rumourwithai.com — Dutch Haul Defies European Pharma Warnings | Rumour With AI
- chinaarticles.substack.com — The Cake that Gerhard Baked - by Matt Turpin
- www.biospace.com — European biotech leaders split on US-China fight for deal ...
-
European Drugmakers Warn of Decline Against US and China
Chairs of nine major European pharmaceutical companies, including AstraZeneca, Novartis, and Roche, warn that the region is losing ground to rivals in the United States and China. The executives are demanding increased spending and faster clinical trials to attract investments in next-generation medicines and prevent the loss of research and drug development. Meanwhile, Western biopharma companies increasingly turn to China for innovation as the industry approaches a patent cliff, and Swiss generics giant Sandoz prepares an EU complaint alleging China dumps subsidized low-priced penicillin.
Why it matters
European pharmaceutical leadership faces mounting pressure as global competitors in the US and China outpace domestic innovation and secure major licensing agreements. Western firms look eastward to source new medical breakthroughs, complicating efforts by European executives to reverse regional decline. At the same time, trade tensions escalate as domestic generics manufacturers demand regulatory intervention against discounted imports.
What is confirmed
- Chairs of nine major European pharmaceutical companies, including AstraZeneca, Novartis, and Roche, signed an open letter urging governments to create conditions that attract investment in next-generation medicines.
- Novartis signed a $7.8 billion Abogen biotech licensing deal.
Still unconfirmed
- Swiss generics giant Sandoz is preparing a complaint to the European Commission against heavily subsidized, low-priced penicillin imports from China.
What to watch next
- Whether the European Commission takes action on the Sandoz complaint regarding Chinese penicillin imports.
- Responses from European governments to the demands for increased spending and faster clinical trials.
confidence 100%Sources used for this update (8)
- www.cnbc.com — Novartis signs $7.8 billion Abogen biotech licensing deal - CNBC
- www.ddw-online.com — Pharma urges leaders to reverse Europe’s declining ...
- www.thepharmaletter.com — Pharma, Biotech and Generics Industry News | The Pharmaletter
- biotechmorning.com — Europe's Pharma Giants Just Sent a 911 Call to Brussels
- gxpnews.net — Eli Lilly’s China vector: how the pharma giant spends its ...
- www.biopharmadive.com — Biotech News | BioPharma Dive
- www.biopharmadive.com — Pharma News | BioPharma Dive
- swissobserver.com — Sandoz Accuses China of 'Dumping' Antibiotics, Seeks EU Action
-
European drugmakers warn of decline, losing ground to US and China
The chairs of nine major European pharmaceutical companies, including AstraZeneca, Novartis, and Roche, have warned that Europe is losing ground to rivals in the US and China. They are calling for increased spending and faster clinical trials to strengthen innovation. Unless urgent action is taken, the region risks losing investment, research, and drug development.
Why it matters
The European pharmaceutical industry faces significant challenges, with a reported $600 billion investment gap compared to the US and China. The decline could have far-reaching consequences for the region's economy and public health. European policymakers are under pressure to address these concerns and create a more attractive environment for innovative medicines.
What is confirmed
- Nine European pharmaceutical companies, including AstraZeneca, Novartis, and Roche, have warned of Europe's decline.
- The companies are calling for increased spending and faster clinical trials to strengthen innovation.
- Europe faces a $600 billion investment gap in the pharmaceutical industry.
- The region risks losing investment, research, and drug development to the US and China.
What to watch next
- European policymakers' response to the open letter
- Changes in investment and clinical trial regulations
- Impact on the European pharmaceutical industry's competitiveness
confidence 100%Sources used for this update (4)
- www.eureporter.co — Nine pharma chiefs urge action as Europe loses ground to US ...
- global.chinadaily.com.cn — Drugmakers sound alarm on Europe's decline - Chinadaily.com.cn
- bizfortune.com — Business Fortune | European Pharmaceutical Industry $600B Gap
- www.dcatvci.org — European Executives Call on National Govt’s To Prioritize ...
-
Nine European Pharma Chairs Warn of Investment Decline
The chairs of nine major pharmaceutical companies warn that Europe is losing ground to rivals in the US and China. In an open letter, leaders from firms including AstraZeneca, Novartis, and Roche state that the region is losing the investment race. They are calling for increased spending and faster clinical trials to strengthen innovation. The executives warn European leaders that future investment is at risk unless the bloc takes urgent action to reverse a perceived slow agony of decline.
Why it matters
Pharmaceutical innovation requires massive capital and rapid regulatory approval to remain competitive. A shift in investment toward the US and China could reduce Europe's capacity to develop new medicines. This move signals a coordinated effort by industry leaders to pressure policymakers for structural reforms.
What is confirmed
- Nine pharmaceutical companies, including AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi, issued a joint open letter.
- European drugmakers state they are losing ground to competitors in the US and China.
- Industry leaders are calling for increased spending and faster clinical trials to compete.
- Pharma executives warned European leaders that future investment is at risk.
Still unconfirmed
- Europe does not value what pharmaceutical companies do.
- European pharma is experiencing a slow agony of decline.
What to watch next
- Official responses from European Union leadership regarding investment incentives.
- Changes to European clinical trial regulations to accelerate timelines.
- New spending commitments from EU member states for pharmaceutical innovation.
confidence 100%Sources used for this update (6)
- The Guardian — European drugmakers say they are ‘losing ground’ to US and Chinese rivals
- Reuters — European drugmakers call for faster trials, more spending to compete with US, China
- Fierce Pharma — 'Europe does not value what you do': 9 pharmas make urgent call for bloc to beef up innovation muscle
- Bloomberg.com — Pharma Bosses Warn European Leaders Future Investment at Risk
- FirstWord — European pharma's 'slow agony' of decline draws warning from nine industry chairs
- AstraZeneca — Europe Is Losing the Pharma Investment Race — But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community